PMDA drug package insert
エベレンゾ錠20mg
PMDA Prescription drug · アステラス製薬株式会社 · package insert May 28, 2025
Key facts
| Brand names | エベレンゾ錠20mg, エベレンゾ錠50mg, エベレンゾ錠100mg |
|---|---|
| Nonproprietary names | ロキサデュスタット |
| Companies | 製造販売／アステラス製薬株式会社, 提携／FibroGen Inc. |
| Product type | Prescription drug |
| Therapeutic category | HIF-PH阻害薬; 腎性貧血治療薬 |
| Therapeutic category codes | 873999 |
| YJ codes | 3999047F1028, 3999047F2024, 3999047F3020 |
| Approval numbers | 30100AMX00239, 30100AMX00240, 30100AMX00241 |
| Package insert edition | 第9版 |
| Package insert date | May 28, 2025 |
| PMDA document key | 800126_3999047F1028_1 |
| PMDA company code | 800126 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: